ezrin和nm-23在乳腺癌中的表达及其临床意义

摘要

目的:研究乳腺癌组织中 ezrin和nm-23蛋白表达与乳腺癌临床因素和预后的关系. 方法: 应用免疫组化S-P方法,检测63例乳腺癌癌组织,20例癌旁组织,及30例乳腺良性肿瘤中的ezrin和nm-23表达.结果: ezrin和nm-23在乳腺良性肿瘤和乳腺癌癌旁组织中均无异常表达.在乳腺癌组织中ezrin和nm-23的表达率分别为55.56%(35/63)和52.38%(33/63),ezrin在乳腺癌中的表达和淋巴结转移,临床分期呈正相关而和无病生存时间呈负相关(P<0.05),nm-23的表达和淋巴结转移,临床分期呈负相关而和无病生存时间呈正相关(P<0.05),ezrin和nm-23在乳腺癌中的表达和年龄、肿块大小以及月经情况无相关性(P>0.05).结论: 检测ezrin和nm-23在乳腺癌中的表达有助于判断乳腺癌的转移潜能和预后.%Objective:To explore the expression and clinical significance of ezrin and nm-23 in breast cancer,and to evaluate the relationship with prognosis. Methods: Immunohistochemical staining(s-p) was used to detect the expression of ezrin and nm-23 in 63 cases of breast cancer,20 cases of corresponding adjacent tissues and 30 cases of benign tumor. Results: No abnormal expression of ezrin and nm-23 in benign tumors and corresponding adjacent tissues was observed. In 63 cases of breast cancer ,the abnomal expression rates of ezrin and nm- 23 were 55.56% and 52.38%(33/63),respectively.The expression of ezrin positively correlated with lymph node metastasis and clinical stage ,while negatively correlated with DFS(P<0.05),nm-23 negatively correlated with lymph node metastasis,clinical stage and positively correlate with DFS(P<0.05),but had no statistical relationship with tumor size,age and menopausal status (P>0.05). Conclusion:Measurement of ezrin and nm-23 expression may have prognostic value for assessing the degree of malignancy and potential lymph node metastasis probability of breast cancer.